1stOncology™: Cancer Intelligence Service – Page 12949 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Agenus to Host R&D Day November 15, 2019

On November 12, 2019 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, reported that it will host an R&D Day on November 15, 2019 (Press release, Agenus, NOV 12, 2019, View Source [SID1234550952]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Date: Friday, November 15, 2019

Time: 11:00AM – 2:00PM

Live webcast: View Source

Location: New York, NY (by invitation only)

Agenus has delivered more I-O discoveries to the clinic in the last three years than any large pharma and is on track to file a BLA in 2020 for accelerated approval of its lead candidates Zalifrelimab (anti-CTLA-4) and Balstilimab (anti-PD-1) while also advancing AGEN1181, a potential best-in-class next generation anti-CTLA-4 antibody, and a pipeline of additional antibodies, cell therapies, and vaccines.

The event will be moderated by Dr. Garo Armen, Chairman and Chief Executive Officer, and Dr. Jennifer Buell, Chief Operating Officer, and will include presentations by world experts in I-O, Dr. Steven O’Day, Executive Director of the John Wayne Cancer Institute, and Dr. Manuel Hidalgo, Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and New York-Presbyterian/Weill Cornell Medical Center.

The event will be webcast live and may be accessed by visiting the "Events & Presentations" page within the Investors section of the Agenus website www.agenusbio.com or by using the link below. A replay of the webcast will be available on the Agenus website following the event.

IGM Biosciences to Present at Three Upcoming Investor Conferences

On November 12, 2019 IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients, reported that Fred Schwarzer, Chief Executive Officer, will present at three upcoming investor conferences (Press release, IGM Biosciences, NOV 12, 2019, View Source [SID1234550951]):

Stifel 2019 Healthcare Conference on Tuesday, November 19 at 4:45 p.m. ET in New York.
Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 11:20 a.m. GMT in London.
Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4 at 3:00 p.m. ET in New York.
A live webcast of the events will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcasts will be archived on the Company’s website for 90 days following the presentation.

FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS

On November 12, 2019 Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, reported its business update and financial results for the third quarter ended September 30, 2019 (Press release, Fennec Pharmaceuticals, NOV 12, 2019, View Source [SID1234550950]).

"We are nearing completion of the NDA for PEDMARK and expect to complete the rolling submission to the FDA in early 2020" said Rosty Raykov, chief executive officer of Fennec. "With the addition of a chief commercial officer during the quarter, we are focused on building the necessary team and infrastructure to support a rapid commercial launch of PEDMARK, if approved, in the second half of 2020."

Financial Results for the Third Quarter 2019

·Cash Position – Cash and cash equivalents were $15.2 million as of September 30, 2019. The reduction in cash balance over the quarter is the result of cash used for operating activities including the manufacturing and regulatory expenses associated with the regulatory submissions of PEDMARKTM.
·R&D Expenses – Research and development (R&D) expenses were $0.8 million for the three months ended September 30, 2019, compared to $1.8 million for the same period in 2018 as the Company completed a significant part of the activities needed for regulatory approval of PEDMARKTM during the first six months of 2019.
·G&A Expenses – General and administrative (G&A) expenses were $1.1 million for the three months ended September 30, 2019, and $1.1 million for the same period in 2018.
·Net Loss – Net loss was $1.8 million and $2.7 million for the three months ended September 30, 2019 and 2018, respectively.
·Financial Guidance – The Company believes its cash and cash equivalents on hand as of September 30, 2019 will be sufficient to fund the Company’s planned commercial launch of PEDMARKTM in the second half of 2020.

Financial Update

The selected financial data presented below is derived from our audited condensed consolidated financial statements which were prepared in accordance with U.S. generally accepted accounting principles. The complete interim unaudited consolidated financial statements for the period ended September 30, 2019 and management’s discussion and analysis of financial condition and results of operations will be available via www.sec.gov and www.sedar.com. All values are presented in thousands unless otherwise noted.

About PEDMARK (Sodium Thiosulfate (STS))

Cisplatin and other platinum compounds are essential chemotherapeutic components for many pediatric malignancies. Unfortunately, platinum-based therapies cause ototoxicity in many patients, and are particularly harmful to the survivors of pediatric cancer.

In the U.S. and Europe there is estimated that over 10,000 children may receive platinum-based chemotherapy. The incidence of hearing loss in these children depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants and young children at critical stages of development lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement.

STS has been studied by cooperative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. Both studies are completed. The COG ACCL0431 protocol enrolled one of five childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

CASI Pharmaceuticals Announces Third Quarter 2019 Financial Results

On November 12, 2019 CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products, reported financial results for the third quarter and nine months ended September 30, 2019 (Press release, CASI Pharmaceuticals, NOV 12, 2019, View Source [SID1234550949]).

Wei-Wu He, Ph.D., CASI’s Chairman and Chief Executive Officer, commented, "We launched EVOMELA in China during the third quarter and completed our transition to a commercial organization. The sales revenue since the launch and the demand for the drug were greater than our initial expectations and we are now working with our partner and manufacturer to accelerate the production timeline of EVOMELA due to this demand. Our successful launch was driven by our strong commercial team which continues to gain significant insight into the hematology oncology market which we believe will be invaluable as we continue launching additional products in this space. We are excited about our momentum and will continue evaluating additional strategic assets to tactically grow our pipeline."

Third Quarter 2019 Financial Results

·Revenues consisted primarily of product sales of EVOMELA that launched in August 2019. Revenue from EVOMELA was $2.7 million for the third quarter 2019. As commercial sales began in August 2019, revenue for the third quarter 2019 only consisted of approximately 1.5 months of sales.

·Costs of goods sold were $2.6 million for the third quarter 2019. Cost of goods sold have been impacted by a transitional supply agreement that is in the process of being modified with an alternate manufacturer. Cost of goods sold also was impacted by certain non-recurring charges associated with the startup production for the commercial launch. With the alternate supply line and the passing of start-up related charges, we expect the Cost of goods sold to be considerably reduced in the future.

CASI Pharmaceuticals, Inc. / 9620 Medical Center Drive / Suite 300 / Rockville, MD 20850

Phone 240.864.2600 / Fax 301.315.2437

·Research and development expenses for the third quarter 2019 were $1.8 million, compared with $1.8 million for the same period in 2018.

·General and administrative expenses for the third quarter 2019 were $8.0 million, compared with $6.9 million for the same period in 2018. The increase is primarily due to support costs related to the launch of EVOMELA that occurred during August 2019.

·Selling and marketing expenses for the third quarter 2019 were $975,000. The increase is due to selling cost related to commercial sales of EVOMELA that began during August 2019.

·Net loss for the third quarter 2019 was $9.7 million compared to $8.8 million for the same period in 2018.

·As of September 30, 2019, CASI had cash and cash equivalents of $63.2 million compared to $84.2 million as of December 31, 2018. The decrease in cash is primarily due to the Black Belt and Juventas investments made during the second quarter 2019, along with normal operating expenses.

Further information regarding the Company, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, can be found at www.casipharmaceuticals.com.

About EVOMELA

EVOMELA (melphalan hydrochloride for injection) is an alkaline drug that is approved and in China is indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma, and for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. EVOMELA was previously granted priority review by the China NMPA because multiple myeloma is classified as a rare disease in China, there is no melphalan in any formulation available in China to address this unmet medical need; and EVOMELA has clear therapeutic advantage to currently available therapeutics.

Coherus BioSciences Management to Present at Two Upcoming Investor Healthcare Conferences

On November 12, 2019 Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), reported that senior management will present at two upcoming investor healthcare conferences (Press release, Coherus Biosciences, NOV 12, 2019, View Source [SID1234550948]).

Management will deliver a company presentation at the Jefferies 2019 London Healthcare Conference on Thursday, November 21st at 9:20 a.m. GMT taking place in London, UK.
Management will deliver a company presentation at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3rd at 1:30 p.m. ET taking place in New York, New York.
The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at View Source